1. World Preview 2017, Outlook to 2022;Evaluate Pharma,2017
2. European Public Assessment Reports;European Medicines Agency,2018
3. Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations;U.S. Food and Drug Administration,2018
4. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product;CDER/CBER, FDA,2015
5. Biological Guidelines;European Medicines Agency,2018